Susan Kweskin

Senator Charles Grassley (R-IA) is continuing his 2-year investigation of potential conflicts of interest between academic researchers and the pharmaceutical industry.

A clinic for patients with bipolar disorder at Massachusetts General Hospital (MGH) was the scene of yet another attack by a patient on a psychiatrist.

In a highly charged environment in which reports of potential conflicts of interest between physicians and pharmaceutical companies dominate the headlines almost daily, we want to point out that the supplements that were mailed with this month’s issue of Psychiatric Times were based on meetings funded by drug companies. The supplement on treatment-resistant depression, which was sponsored by Lilly USA,includes an article that focuses on the company’s drug Symbyax.

I couldn't help but notice that it has become possible lately to lift recent editions of the Sunday New York Times with only a single hand. Not too long ago, the Sunday edition had a lot more reassuring heft to it.